scholarly journals Human papillomavirus infections and cervical cancer screening in Tunisian women

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
H Bouguerra ◽  
A Hechaichi ◽  
H Letaief ◽  
M Ardhaoui ◽  
E Ennaiefer ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Cervical Screening ◽  
Public Health Problem ◽  
Hpv Infection ◽  
High Risk Hpv ◽  
National Prevalence

Abstract Background Human papillomavirus (HPV) infections are a significant public health problem with global estimations over 520 000 new cases and 274 000 deaths due to cervical cancer. In Tunisia, cervical cancer is the third cause of cancer in women but only a few prevalence studies conducted in specific populations are available. The present study aims to estimate the national prevalence of HPV infection and cervical cancer testing among Tunisian women. Methods We conducted a population-based cross-sectional study in 2014. We included all sexually active women aged 18 years and older, present in primary health care centers the day of the study. Data collection was based on a standardized questionnaire including socio-demographic data, high-risk behaviors and previous cervical screening. HPV detection and typing was only done for betaglobin positive PCR-test. Ethical considerations were respected. Results The total number of surveyed women was 1494 and the overall prevalence of HPV infection was 7.5% IC95% [5.9%-9.0%]. The most common genotypes were HPV6 (21.9%) and HPV16 (11.5%). Prevalence of high-risk HPV was higher than low-risk HPV; 4.8% IC95% [3.7%-6.2%] and 3.8% IC95% [2.8%-4.8%] respectively. The prevalence of previous cervical screening was 36.6% (95% CI [34.3%-39.2%]). This rate was significantly associated with age (p < 10-3); from 13.9% among those <30 years to 49.3% among those ≥ 50 years. Conclusions Our survey provides an important overview of the current situation of HPV infection among Tunisian women. National prevalence of HPV infection was 7.5% but only 36.6% of women had a previous cervical cancer screening. This coverage remains poor, thus the need of targeted education and encouraging strategies to reduce cervical cancer burden in Tunisia. Key messages National prevalence of HPV infection is not negligeable in Tunisia, especially high risk HPV infections. Cervical screening is still low among Tunisian women, hence the need for education targeted to this population.

scholarly journals Comparison of detection rate of high risk HPV infection between self-collected HPV testing and clinician-collected HPV testing in cervical cancer screening

2019 ◽  
Vol 58 (4) ◽  
pp. 477-481 ◽  
Author(s):  
Pattiya Nutthachote ◽  
Shina Oranratanaphan ◽  
Wichai Termrungruanglert ◽  
Surang Triratanachat ◽  
Arkom Chaiwongkot ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Detection Rate ◽  
Hpv Infection ◽  
Hpv Testing ◽  
High Risk Hpv

scholarly journals Prevalence of High-risk Human Papillomavirus Infection Among Prisoners in the Nsawam Medium Security Prison, Ghana

2020 ◽  
Author(s):  
Lawrence Kofi Acheampong ◽  
Kofi Effah ◽  
Joseph Emmanuel Amuah ◽  
Ethel Tekpor ◽  
Comfort Mawusi Wormenor ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Prevalence Rate ◽  
Prison Population ◽  
Hpv Infection ◽  
Thermal Coagulation ◽  
Hpv Test ◽  
High Risk Hpv

Abstract Background: The Ghana Prisons Service has a Health Directorate that ensures delivery of healthcare to people in their custody under the Ghana Association of Quasi Health Institution (GAQHI) which is one of the agencies under the Ministry of Health. Across Ghana, females comprise 1.2% of the entire prison population (n=15,463). Cervical cancer screening services are however nonexistent and the prevalence of cervical precancer is undocumented. Our aim was to determine the prevalence of high-risk HPV infection and associated cervical abnormalities during a cervical cancer screening outreach. Methods: After informed consent and counselling, women underwent a structured questionnaire-based interview. Responses were recorded directly into a Microsoft Excel spreadsheet. Inmates were co-tested for cervical pre-cancer by two trained nurses using dry brush cervical samples for 15 high risk HPV types using the AmpFire HPV test after which mobile colposcopy with the EVA system was performed. EVA images were reviewed by a gynecologist. Frequencies and percentages were used to describe categorical data while means and standard deviations or medians and interquartile ranges were used to describe continuous data. Results: The majority (75%) of the inmates were convicts with a median sentence of 5 years. Their mean age was 41.1 years (range, 19–97). Out of the 14% that had ever been screened for cervical cancer, 75% had only been screened once. The self-reported prevalence rate of HIV among the inmates was 13.1%, all of who were receiving treatment. The high-risk HPV prevalence rate was 47.6% in the general population of inmates and 63.6% among HIV positive inmates. Using the EVA system, 5(6%) had lesions on the cervix of which 3(3.6%) were treated with thermal coagulation and 2(2.4%) were treated with LEEP. The average age of high-risk HPV positive inmates was 37.8 years. These inmates were also more likely to have been in prison for a shorter duration. Conclusion: There is a high prevalence of high-risk HPV infection among women in custody. These women will benefit from structured cervical cancer prevention services, including treatment for abnormalities that are picked up during such screening.

scholarly journals Review of Research on the Prevention of HPV Infection and Cervical Cancer

2016 ◽  
Vol 5 (2) ◽  
pp. 39-43
Author(s):  
Tao Wang
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Epidemiological Survey ◽  
Hpv Infection ◽  
Hpv Testing ◽  
Prevention And Treatment ◽  
Preventive Vaccination ◽  
High Risk Hpv

AbstractWorldwide, cervical cancer remains as one of the most common malignancies that threaten women's health. An epidemiological survey has shown that high-risk chronic HPV infection is the leading cause of cervical cancer. Thus, the prevention of HPV infection is the main approach to the prevention and treatment of cervical cancer. Sexual behavior, individual immunity, and age are important cofactors in the promotion of HPV infection. Preventive measures that have been gradually implemented worldwide have significantly decreased the incidence of cervical cancer in recent years. These measures include preventive vaccination against common high-risk HPV and cervical cancer screening, which includes HPV testing. HPV testing in cervical cancer screening has received increased attention and provides the basis for the prevention and treatment of cervical cancer. Given that HPV infection rates significantly vary from region to region, procedures for cervical cancer screening should be improved based on regional differences.

Human papillomavirus in cervical screening and vaccination

2006 ◽  
Vol 110 (5) ◽  
pp. 543-552 ◽  
Author(s):  
Emma J. Crosbie ◽  
Henry C. Kitchener
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
Residual Disease ◽  
Cervical Screening ◽  
Hpv Infection ◽  
Hpv Testing ◽  
Hpv Dna ◽  
Hpv Test ◽  
High Risk Hpv

Recent decades have witnessed a reduction in the incidence of cervical cancer in countries where screening programmes have achieved broad coverage. The recognized importance of high-risk HPV (human papillomavirus) infection in the aetiology of cervical cancer may introduce a role for HPV DNA testing in cervical screening programmes. Positive HPV DNA tests indicate women at risk of cervical cancer with greater sensitivity, but reduced specificity, compared with exfoliative cytology. Combining HPV testing with cytology may be useful in the triage of minor cytological abnormalities into those requiring referral to colposcopy (HPV positive) compared with those who can be safely managed by cytological surveillance (HPV negative). With its high sensitivity and high-negative-predictive value, HPV testing may also be useful for predicting treatment failure, since residual disease is very unlikely in the event of a negative HPV test. Ultimately, prevention is better than cure, and the advent of HPV prophylactic vaccines may obviate the need for population-based cervical screening programmes in the future. A multivalent vaccine administered to adolescents prior to the onset of sexual activity and boosted at regular intervals throughout their sexually active life may provide protection against type-specific HPV infection, malignant precursors and invasive cervical disease. Several large randomized placebo-controlled trials have been conducted with promising results. For those generations of women already exposed to high-risk HPV infection, therapeutic vaccines may offer advantages over conventional treatment, although much work still needs to be done.

scholarly journals Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings

2019 ◽  
Vol 58 (1) ◽  
Author(s):  
Anja Oštrbenk Valenčak ◽  
Anja Šterbenc ◽  
Katja Seme ◽  
Mario Poljak
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Cervical Intraepithelial Neoplasia Grade ◽  
International Consensus ◽  
Clinical Sensitivity ◽  
Hpv Dna ◽  
High Risk Hpv

ABSTRACT The Alinity m HR HPV assay (Alinity) is a novel human papillomavirus (HPV) assay that individually identifies genotypes HPV16, HPV18, and HPV45 while reporting on 11 other high-risk HPV (hrHPV) genotypes in two aggregates: HPV31/33/52/58 and HPV35/39/51/56/59/66/68. The clinical performance of Alinity for screening for cervical cancer was evaluated in population-based settings. For women aged ≥30 years, the clinical sensitivity (n = 68) and specificity (n = 3,077) for the detection of cervical intraepithelial neoplasia grade 2+ (CIN2+) of Alinity were 100.0% and 92.4%, respectively, and were not inferior to those of the Qiagen Digene Hybrid Capture 2 high-risk HPV DNA assay (hc2) (P = 0.0006 and P < 0.0001, respectively). The intralaboratory reproducibility and interlaboratory agreement of Alinity were 96.7% (kappa, 0.92) and 98.7% (kappa, 0.97), respectively. In the group ≥30 years of age, women who were baseline hrHPV negative had a lower risk for CIN2+ at 3 years using Alinity (0.04%) than those with a normal baseline cytology (0.65%) and had a risk comparable to that determined by the Abbott RealTime High Risk HPV assay (0.04%), hc2 (0.08%), or the Roche Cobas 4800 HPV assay (0.04%). High-risk HPV16/18 infection was associated with a significantly higher baseline and 3-year CIN2+ and CIN3+ risk than the absence of HPV16/18 or the presence of hrHPVs at the baseline (all P values were <0.05). The baseline CIN2+ risk was 8.8% for those with HPV31/33/52/58 infection and 2.5% for those with HPV35/39/51/56/59/66/68 infection, while the 3-year CIN2+ risk was 17.0% and 4.9%, respectively (relative risk, 3.4 [P = 0.03] and 3.5 [P = 0.003], respectively), suggesting that extended genotyping by Alinity may be valuable in improving patient risk stratification. Alinity fulfills international consensus guideline criteria for primary cervical cancer screening and can be considered clinically validated, demonstrating safety comparable to that of other clinically validated HPV tests.

scholarly journals Molecular characterization of high-risk human papillomavirus (HR-HPV) in women in Lomé, Togo

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Akouélé P. Kuassi-Kpede ◽  
Essolakina Dolou ◽  
Théodora M. Zohoncon ◽  
Ina Marie Angèle Traore ◽  
Gnatoulma Katawa ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
West Africa ◽  
Public Health Problem ◽  
Hpv Infection ◽  
Cervical Lesions ◽  
Hpv Genotypes ◽  
Precancerous Cervical Lesions ◽  
High Risk Hpv ◽  
First Time

Abstract Background The causative agent of cervical cancer referred to as Human papillomavirus (HPV) remains a real public health problem. Many countries in West Africa, such as Togo have no data on the high-risk HPV (HR-HPV) infection and genotypes distribution. In order to fill the knowledge gap in the field in Togo, the main objective of this study was to determine the prevalence of pre-cancerous lesions of the cervix and HR-HPV genotypes among Togolese women. Methods Samples were collected from 240 women by introducing a swab in the cervix. Then, the screening of precancerous cervical lesions using the visual inspection with acetic acid and lugol (VIA / VIL) was conducted. The HR-HPV genotypes were characterised by real-time multiplex PCR. Results Out of 240 women recruited, 128 (53.3%) were infected by HR-HPV. The most common genotypes were HPV 56 (22.7%), followed by HPV 51 (20.3%), HPV 31 (19.5%), HPV 52 (18.8%) and HPV 35 (17.2%). The least common genotypes were HPV 33 (2.3%) and HPV 16 (2.3%). Among the women, 1.3% (3/240) were positive to VIA/VIL. Conclusion This study allowed HR-HPV genotypes to be characterised for the first time in Lomé, Togo. This will help in mapping the HR-HPV genotypes in West Africa.

Sign in / Sign up

Export Citation Format

Share Document